Last updated on October 2017

Dose Response Study of EMA401 in Patients With Post-herpetic Neuralgia (PHN)


Brief description of study

To characterize dose response, and evaluate safety and efficacy of three different doses of EMA401 compared to placebo in patients with post-herpetic neuralgia (PHN)

Clinical Study Identifier: NCT03094195

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Novartis Pharmaceuticals

Novartis Investigative Site
Klagenfurt, Austria
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Vienna, Austria
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Odense C, Denmark
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
LILLE Cédex, France
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Nice, France
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Essen, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Kiel, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Oslo, Norway
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Presov, Slovakia
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Darlington, United Kingdom
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Edinburgh, United Kingdom
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Liverpool, United Kingdom
  Connect »